January 2023 Legislative & Regulatory Briefing: The PIE Act of 2022 Becomes Law; Member Benefit! Stay Up to Date on IRA Guidance with Regulatory NewsBREAKs; Media Coverage Captures Its Own Piece of the PIE; Reimbursement for PDTs Could Increase Access to Emerging Treatments; Registration is Now Open for AMCP 2023 in San Antonio.
Hemophilia, sickle cell disease (SCD), and beta-thalassemia (β thal) are inherited blood disorders likely to see multiple significant novel therapies approved in the near future, including the possibility for partial or complete cures with gene therapies. To understand the appropriate and cost-effective use of treatments for inherited blood disorders, AMCP convened an expert panel of managed care stakeholders in October 2022.
Chronic lymphocytic leukemia (CLL) is characterized by a progressive accumulation of leukemia cells in the peripheral blood, bone marrow, and lymphoid tissues. Bruton tyrosine kinase inhibitors (BTKis) are a preferred treatment of patients with CLL. In September 2022, AMCP convened an expert panel of managed care stakeholders to better understand the clinical dynamics of treatment choice in patients with CLL and the key management considerations in CLL with a focus on BTKis.
AMCP applauds Congress for passing the Pre-approval Information Exchange (PIE) Act of 2022. This bipartisan bill will enhance proactive information-sharing on new treatments between drug manufacturers and health plans.
Alopecia areata is a disease that happens when the immune system attacks hair follicles and causes hair loss. While hair can be lost from any part of the body, alopecia areata usually affects the head and face.
December 2022 Legislative & Regulatory Briefing: The PIE Act Makes Waves in Washington D.C.; Member Benefit! Read the Latest Regulatory NewsBREAKs; AMCP CEO Susan A. Cantrell Applauds Reintroduction of the PIE Act; AMCP Joins Pharmacy Organizations in Request for Medicaid Guidance to States; AMCP's Adam Colborn Featured in Politico Pro.